Public-registry site landscape for NCT03630952, a Neovascular Age-related Macular Degeneration study sponsored by Chengdu Kanghong Biotech Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03630952 (registry record) |
| Sponsor | Chengdu Kanghong Biotech Co., Ltd. |
| Condition(s) | Neovascular Age-related Macular Degeneration |
| Phase | PHASE3 |
| Listed sites | 154 |
| Site countries | United States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT03630952 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →